Robinin attenuates DMH-induced colon cancer in rats by modulating Ras/PI3K/Akt/mTOR and NF-κB pathways
Background
Colorectal cancer (CRC) is the third most frequent cancer globally, with high mortality rates, necessitating innovative therapeutic strategies. Current treatments often face challenges in efficacy and specificity, highlighting the need for novel agents that target fundamental molecular mechanisms. Flavonoids like Robinin (RB), derived from Astragalus species, are gaining attention for their diverse pharmacological properties, including antioxidative, anti-inflammatory, and antitumor effects, making them promising candidates for CRC intervention by addressing key pathways like inflammation and apoptosis.
Study Design
Researchers investigated Robinin's anticancer effects in a 1,2-dimethylhydrazine (DMH)-induced colorectal cancer rat model over 15 weeks. Rats were divided into six groups: Normal Control (NC), CRC Control (DMH, 20 mg/kg/week, i.p.), Robinin treatment groups (DMH + RB at 5, 10, and 20 mg/kg bw), and an RB-alone group (20 mg/kg bw). Primary endpoints included tumor volume and number, incidence of aberrant crypt foci (ACF), crypt count, and crypt multiplicity. They also assessed weight loss, inflammatory cytokine levels, histopathological changes, and performed IHC for Bax, Caspase-3, and NF-κB, alongside cAMP and hepatic xenobiotic enzyme activity measurements.
Results
DMH-alone rats exhibited 100% incidence of CRC, with significantly elevated (p < 0.01) tumor volume, number, ACF incidence, crypt count, and crypt multiplicity. Robinin treatment, however, dose-dependently reduced (p < 0.05) these pre-cancerous lesions. The highest dose of Robinin (20 mg/kg bw) demonstrated the most pronounced effects. Robinin also effectively diminished DMH-induced weight loss and inflammatory cytokine levels, while restoring cAMP and normalizing hepatic xenobiotic enzyme activities. Histopathological alterations were significantly ameliorated, and IHC analysis revealed reduced expression of NF-κB and increased expression of pro-apoptotic markers Bax and Caspase-3 in Robinin-treated groups. These beneficial effects were attributed to Robinin's ability to modulate critical signaling pathways.
Robinin significantly attenuated DMH-induced colon cancer progression by targeting the
Ras/PI3K/Akt/mTORandNF-κB/Bax/Caspase-3signaling pathways.
Key Findings
- Robinin dose-dependently reduced pre-cancerous lesions (ACF, crypts, multiplicity) in DMH-induced rats (p < 0.05).
- Robinin diminished DMH-induced tumor volume and number, and prevented weight loss.
- Robinin reduced inflammatory cytokine levels and ameliorated histopathological alterations.
- Robinin modulated
NF-κB,Bax, andCaspase-3expression, promoting apoptosis. - Robinin regulated
Ras/PI3K/Akt/mTORsignaling pathways in colon cancer.
Why It Matters
This study highlights Robinin as a promising natural compound for colorectal cancer prevention and treatment, offering a multi-targeted approach by simultaneously addressing inflammation, apoptosis, and key oncogenic signaling pathways. For individuals exploring natural compounds or adjunctive therapies, Robinin's ability to modulate multiple cancer-driving pathways suggests a broad therapeutic potential beyond single-target drugs. While this is a preclinical animal study, the detailed mechanistic insights into Ras/PI3K/Akt/mTOR and NF-κB pathways provide a strong foundation for future human clinical trials. The dose-dependent effects observed in rats also offer initial guidance for potential therapeutic concentrations, although direct translation to human dosing requires further research.
robinin
colorectal-cancer
crc
preclinical-animal
ras-pi3k-akt-mtor
nf-kb